DelveInsight’s “Pleural Diseases Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Pleural Diseases, historical and forecasted epidemiology as well as the Pleural Diseases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Pleural Diseases market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pleural Diseases Market Forecast
Some of the key facts of the Pleural Diseases Market Report:
The Pleural Diseases market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
The FDA granted approval for the use of Skytrofa (lonapegsomatropin) in September 2021 for the treatment of pediatric patients aged one year and older who weigh at least 11.5 kg and have growth failure as a result of insufficient endogenous growth hormone secretion
The study by Rogol stated that GHD in children is a relatively rare condition. In the United States, it was estimated to occur in approximately 1 in 3500 to 4000 children
As per National Institute for Health and Clinical Excellence (NICE), the prevalence of growth hormone deficiency was estimated to be between 1 in 3500 and 1 in 4000 children
In about half of the children with growth hormone deficiency (50%), the cause is unknown (idiopathic growth hormone deficiency)
Key Pleural Diseases Companies: Istituto Oncologico Veneto, RS Oncology, PrECOG, LLC, AstraZeneca, Oncotelic Inc., Trizell Ltd, MedImmune LLC, Sanofi, and others
Key Pleural Diseases Therapies: Carboplatin, RSO-021, Durvalumab, Volrustomig, OT-101, rAd-IFN, Tremelimumab, THOR-707, and others.
The Pleural Diseases market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pleural Diseases pipeline products will significantly revolutionize the Pleural Diseases market dynamics.
Pleural Diseases Overview:
Pleural diseases refer to medical conditions that affect the pleura, the thin membrane surrounding the lungs and lining the chest cavity. Common pleural diseases include pleurisy (inflammation of the pleura), pleural effusion (excess fluid in the pleural space), pneumothorax (collapsed lung), and pleural thickening. These conditions can result from infections, injuries, cancers, or autoimmune disorders and often cause symptoms like chest pain, shortness of breath, and coughing. Diagnosis and treatment depend on the underlying cause and severity of the condition.
Get a Free sample for the Pleural Diseases Market Report:
https://www.delveinsight.com/report-store/pleural-diseases-market
Pleural Diseases Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Pleural Diseases Epidemiology Segmentation:
The Pleural Diseases market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Pleural Diseases
Prevalent Cases of Pleural Diseases by severity
Gender-specific Prevalence of Pleural Diseases
Diagnosed Cases of Episodic and Chronic Pleural Diseases
Download the report to understand which factors are driving Pleural Diseases epidemiology trends @ Pleural Diseases Epidemiology Forecast
Pleural Diseases Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pleural Diseases market or expected to get launched during the study period. The analysis covers Pleural Diseases market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pleural Diseases Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Pleural Diseases Therapies and Key Companies
Carboplatin: Istituto Oncologico Veneto
RSO-021: RS Oncology
Durvalumab: PrECOG, LLC.
Volrustomig: AstraZeneca
OT-101: Oncotelic Inc.
rAd-IFN: Trizell Ltd
Tremelimumab: MedImmune LLC
THOR-707: Sanofi
Discover more about therapies set to grab major Pleural Diseases market share @ Pleural Diseases Treatment Market
Scope of the Pleural Diseases Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Pleural Diseases Therapies: Carboplatin, RSO-021, Durvalumab, Volrustomig, OT-101, rAd-IFN, Tremelimumab, THOR-707, and others
Pleural Diseases Therapeutic Assessment: Pleural Diseases current marketed and Pleural Diseases emerging therapies
Pleural Diseases Market Dynamics: Pleural Diseases market drivers and Pleural Diseases market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Pleural Diseases Unmet Needs, KOL’s views, Analyst’s views, Pleural Diseases Market Access and Reimbursement
To know more about Pleural Diseases companies working in the treatment market, visit @ Pleural Diseases Clinical Trials and Therapeutic Assessment
Table of Contents
1. Pleural Diseases Market Report Introduction
2. Executive Summary for Pleural Diseases
3. SWOT analysis of Pleural Diseases
4. Pleural Diseases Patient Share (%) Overview at a Glance
5. Pleural Diseases Market Overview at a Glance
6. Pleural Diseases Disease Background and Overview
7. Pleural Diseases Epidemiology and Patient Population
8. Country-Specific Patient Population of Pleural Diseases
9. Pleural Diseases Current Treatment and Medical Practices
10. Pleural Diseases Unmet Needs
11. Pleural Diseases Emerging Therapies
12. Pleural Diseases Market Outlook
13. Country-Wise Pleural Diseases Market Analysis (2019–2032)
14. Pleural Diseases Market Access and Reimbursement of Therapies
15. Pleural Diseases Market drivers
16. Pleural Diseases Market barriers
17. Pleural Diseases Appendix
18. Pleural Diseases Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
